

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM801715

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Intellectual Property Security Agreement		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
9 Meters Bipharma, Inc.		07/15/2022	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	High Trail Special Situations LLC		
Street Address:	c/o High Trail Capital, 80 River Street, Suite 4C		
City:	Hoboken		
State/Country:	NEW JERSEY		
Postal Code:	07030		
Entity Type:	Limited Liability Company: DELAWARE		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	6725571	9METERS BIOPHARMA	
Registration Number:	6647940	CEDLARA	
CORRESPONDENCE DATA			
Fax Number:	2138918763		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Email:	rhonda.deleon@lw.com		
Correspondent Name:	LATHAM & WATKINS LLP		
Address Line 1:	355 SOUTH GRAND AVENUE		
Address Line 4:	LOS ANGELES, CALIFORNIA 90071-1560		
ATTORNEY DOCKET NUMBER:	065377-0024		
NAME OF SUBMITTER:	Rhonda DeLeon		
SIGNATURE:	/Rhonda DeLeon/		
DATE SIGNED:	04/10/2023		
Total Attachments: 17			
source=High Trail - NMTR - IP Security Agreement (Executed)#page1.tif			
source=High Trail - NMTR - IP Security Agreement (Executed)#page2.tif			
source=High Trail - NMTR - IP Security Agreement (Executed)#page3.tif			
source=High Trail - NMTR - IP Security Agreement (Executed)#page4.tif			
source=High Trail - NMTR - IP Security Agreement (Executed)#page5.tif			

OP \$65.00 6725571

source=High Trail - NMTR - IP Security Agreement (Executed)#page6.tif
source=High Trail - NMTR - IP Security Agreement (Executed)#page7.tif
source=High Trail - NMTR - IP Security Agreement (Executed)#page8.tif
source=High Trail - NMTR - IP Security Agreement (Executed)#page9.tif
source=High Trail - NMTR - IP Security Agreement (Executed)#page10.tif
source=High Trail - NMTR - IP Security Agreement (Executed)#page11.tif
source=High Trail - NMTR - IP Security Agreement (Executed)#page12.tif
source=High Trail - NMTR - IP Security Agreement (Executed)#page13.tif
source=High Trail - NMTR - IP Security Agreement (Executed)#page14.tif
source=High Trail - NMTR - IP Security Agreement (Executed)#page15.tif
source=High Trail - NMTR - IP Security Agreement (Executed)#page16.tif
source=High Trail - NMTR - IP Security Agreement (Executed)#page17.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of July 15, 2022 among 9 Meters Biopharma Inc., a Delaware corporation (the “Issuer”), Naia Rare Diseases, LLC, a Delaware limited liability company (the “Subsidiary Grantor” and, together with the Pledgor, the “Grantors”) and High Trail Special Situations LLC, a Delaware limited liability company, in its capacity as collateral agent for the benefit of the Holders (together with its successors and assigns in such capacity, the “Secured Party”).

WHEREAS, the Issuer has entered into that certain Securities Purchase Agreement, dated as of June 30, 2022 (as amended, restated, supplemented or otherwise modified from time to time, the “Securities Purchase Agreement”), with High Trail Special Situations LLC (the “Initial Holder”) and each other party thereto, pursuant to which, among other things, the Issuer will issue, and the Initial Holder will purchase, subject to the terms set forth therein, the Senior Secured Notes (as defined in the Securities Purchase Agreement);

WHEREAS, the Grantors have entered into that certain Security Agreement, dated as of July 15, 2022 (as amended, restated, supplemented or otherwise modified from time to time, the Security Agreement”), with the Secured Party, pursuant to which the Grantors granted to the Secured Party, for its benefit and the benefit of the Initial Holder and each Holder under and as defined in any Senior Secured Note (the “Holders”), a security interest in substantially all of the Grantors’ personal property; and

WHEREAS, it is covenant under the Security Agreement that the Grantors shall have executed and delivered this Agreement to the Secured Party for its benefit and the benefit of the Holders.

NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows:

Section 1. DEFINED TERMS; RULES OF CONSTRUCTION.

- (a) Capitalized terms used in this Agreement but not otherwise defined herein have the meanings given to them in the Security Agreement.
- (b) When used herein the following terms shall have the following meanings:

“PTO” means the United States Patent and Trademark Office and any successor office or agency.

- (c) All Schedules, Addenda, Annexes and Exhibits hereto or expressly identified to this Agreement are incorporated herein by reference and taken together with this Agreement constitute but a single agreement. The words “herein”, “hereof” and “hereunder” or other words of similar import refer to this Agreement as a whole, including the Exhibits, Addenda, Annexes and Schedules thereto, as the same may be from time to time amended, modified, restated or supplemented, and not to any

particular section, subsection or clause contained in this Agreement. Wherever from the context it appears appropriate, each term stated in either the singular or plural shall include the singular and the plural, and pronouns stated in the masculine, feminine or neuter gender shall include the masculine, the feminine and the neuter. The term “or” is not exclusive. The term “including” (or any form thereof) shall not be limiting or exclusive. All references to statutes and related regulations shall include any amendments of same and any successor statutes and regulations. All references in this Agreement or in the Schedules, Addenda, Annexes and Exhibits to this Agreement to sections, schedules, disclosure schedules, exhibits, and attachments shall refer to the corresponding sections, schedules, disclosure schedules, exhibits and attachments of or to this Agreement. All references to any instruments or agreements, including references to any of this Agreement, the Security Agreement or the other Note Documents shall include any and all modifications or amendments thereto and any and all extensions or renewals thereof.

- (d) The parties acknowledge that each party and its counsel have reviewed this Agreement and that the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement or any amendments, schedules or exhibits thereto.

Section 2. GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY COLLATERAL. To secure the prompt payment and performance in full when due (whether at stated maturity, by acceleration or otherwise) of the Obligations, each Grantor hereby pledges and grants to the Secured Party (for its benefit and the ratable benefit of the Holders) a continuing security interest in and Lien upon all of such Grantor’s right, title and interest in, to and under the following, whether presently existing or hereafter created or acquired (collectively, the “Collateral”):

- (a) Trademarks to which it is a party, including those referred to on Schedule I hereto;
- (b) Patents to which it is a party, including those referred to on Schedule II hereto;
- (c) Copyrights to which it is a party, including those referred to on Schedule III hereto;
- (d) Renewals, reissues, continuations, continuations-in-part, reexaminations, divisions, or extensions of any of the foregoing;
- (e) Rights to sue, whether at law or in equity, third parties for past, present or future infringement, dilution, misappropriation, or other violation or impairment of rights in any Intellectual Property, including injury to the goodwill associated with any Trademark, and all causes of action for the same; and
- (f) All products and Proceeds of all or any of the foregoing, tort claims and all claims and other rights to payment including (i) insurance claims against third parties for loss of, damage to, or destruction of, the foregoing Collateral and (ii) payments due

or to become due under licenses of any or all of the foregoing and Proceeds payable under, or unearned premiums with respect to policies of insurance in whatever form; provided, however, that the Collateral shall not constitute a grant of a security interest in any trademark or service mark applications filed in and accepted by the PTO on the basis of such Grantor's intent to use such trademark or service mark, unless and until a statement of use or amendment to allege use is filed in and accepted by the PTO, in which event, such trademark or service mark shall automatically be included in the Collateral, or in any rights arising under any contracts, instruments, licenses or other documents as to which the grant of a security interest would violate or invalidate any such contract, instrument, license or other document or give any other party to such contract, instrument, license or other document the right to terminate its obligations thereunder.

Section 3. REPRESENTATIONS AND WARRANTIES.

Each Grantor represents and warrants to the Secured Party, in addition to the representations and warranties in the Security Agreement and the other Note Documents, that:

- (a) such Grantor has been, in all material respects (i) using statutory notice of registration in connection with its use of registered Trademarks, (ii) proper marking practices in connection with the use of Patents, and (iii) appropriate notice of copyright in connection with the publication of copyrighted material;
- (b) such Grantor has taken all actions it deems necessary in its reasonable business judgment to ensure that all licensees of Trademarks owned by such Grantor use consistent standards of quality as directed by such Grantor in connection with its licensed products and services; and

Section 4. COVENANTS. Each Grantor covenants and agrees with the Secured Party, from and after the date of this Agreement, and in addition to the covenants in the Security Agreement and the other Note Documents, that:

- (a) Such Grantor shall notify the Secured Party promptly if it knows that any application or registration relating to any material Intellectual Property owned by such Grantor has or may become abandoned, dedicated to the public, placed in the public domain or otherwise invalidated or unenforceable. Such Grantor shall further notify the Secured Party promptly of any adverse final determination or decision in any proceeding and the institution of any proceeding challenging such Grantor before the PTO, the United States Copyright Office, or any similar agency of the United States, any State, or other country or political subdivision thereof, any internet domain registry or other registry, or any court, regarding such Grantor's ownership of or right to use, register, keep and/or maintain any Intellectual Property. Such Grantor shall be free to prosecute and maintain its Intellectual Property in the ordinary course of business in a commercially reasonable manner, and, notwithstanding the foregoing, shall not be required to report preliminary or initial determinations, unless and until made final, by the PTO, the United States Copyright Office, or any similar agency of the United States, any State, or other

country or political subdivision thereof, any internet domain registry or other registry, or any court, regarding such Grantor's ownership of or right to use, register, keep and/or maintain any Intellectual Property;

- (b) Such Grantor shall (i) prosecute diligently any patent, trademark, or service mark applications pending as of the date hereof or hereafter if material to the operations of the business of such Grantor, (ii) preserve and maintain all rights in the Copyrights, Patents and Trademarks, to the extent material to the operations of the business of such Grantor and (iii) ensure that the Copyrights, Patents and Trademarks are and remain enforceable, to the extent material to the operations of the business of such Grantor. Any expenses incurred in connection with such Grantor's obligations under this Section 4(b) shall be borne by the Grantors. Except for any such items that such Grantor reasonably believes (using prudent industry customs and practices) are no longer necessary for the on-going operations of its business, such Grantor shall not abandon any material right to file a patent, trademark or service mark application, or abandon any pending patent, trademark or service mark application or any other Copyright, Patent or Trademark without the prior written consent of the Secured Party, which consent shall not be unreasonably withheld;
- (c) In the event that any Intellectual Property owned by or exclusively licensed to such Grantor is known by such Grantor to be infringed, diluted, misappropriated, or otherwise violated by a third party, such Grantor shall notify the Secured Party promptly after such Grantor learns thereof and, if such Intellectual Property is material to the conduct of such Grantor's business, such Grantor shall, subject to Grantor's reasonable business judgment, promptly take all commercially reasonable actions to protect and enforce its rights in such Intellectual Property and to recover all damages therefor, including, but not limited to, the initiation of a suit for injunctive relief and damages where reasonable and cost effective to do so (provided that such Grantor must initiate suit in all cases where the failure to do so could reasonably be expected to have a Material Adverse Effect) and shall take such other actions as are commercially reasonable to protect such Grantor's rights in such Intellectual Property;
- (d) Such Grantor shall use appropriate statutory notice of registration in connection with its use of registered Trademarks, proper marking practices in connection with the use of Patents, appropriate notice of copyright in connection with the publication of copyrighted materials, and other legends or markings applicable to other Intellectual Property;
- (e) Such Grantor shall use commercially reasonable efforts to maintain the level of the quality of products sold and services rendered under any Trademarks owned by such Grantor at a level at least consistent with the quality of such products and services as of the date hereof, and such Grantor shall use commercially reasonable efforts to adequately control the quality of goods and services offered by any licensees of its Trademarks;

- (f) Such Grantor shall take reasonable steps to protect the secrecy of all trade secrets material to its business;
- (g) To the knowledge of such Grantor, such Grantor's use of the Intellectual Property owned by such Grantor is not infringing upon or misappropriating, or otherwise violating, the Intellectual Property rights of any third party in any material respect; and
- (h) If such Grantor shall obtain ownership of or other right, title or interest in or to, any registered Copyrights, issued or applied-for Patents, registered or applied-for Trademarks, the provisions of this Agreement above shall automatically apply thereto and such Grantor shall promptly give to the Secured Party written notice thereof in accordance with Section 2(g) of the Security Agreement. Such Grantor hereby authorizes the Secured Party to modify this Agreement by amending Schedules I, II, and III hereto, as applicable, to include any Copyrights, Patents, and Trademarks that have been included in any updated Schedules III, V and/or VI to the Security Agreement pursuant to Section 2(g) of the Security Agreement, and to execute and deliver any supplement hereto (in form and substance reasonably satisfactory to the Secured Party) to evidence the Secured Party's lien on any such Patent, Trademark, or Copyright.

Section 5. SECURITY AGREEMENT. The security interests granted pursuant to this Agreement are granted in conjunction with the security interests granted by the Grantors to the Secured Party, for its benefit and the benefit of the Holders pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Secured Party with respect to the Collateral made and granted herein are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. Any rights and remedies set forth herein are without prejudice to, and in addition to, those set forth in the Security Agreement. In the event any provisions contained herein expressly conflict with any provisions in the Security Agreement covering Intellectual Property, the provisions of the Security Agreement shall control.

Section 6. REINSTATEMENT. This Agreement shall remain in full force and effect and continue to be effective should any petition be filed by or against the Grantors for liquidation or reorganization, should any Grantor become insolvent or make an assignment for the benefit of any creditor or creditors or should a receiver or trustee be appointed for all or any significant part of any Grantor's assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Obligations, whether as a "voidable preference", "fraudulent conveyance" or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

Section 7. NOTICES. Whenever it is provided herein that any notice, demand, request, consent, approval, declaration or other communication shall or may be given to or served upon any of the parties by any other party, or whenever any of the parties desires to give and serve upon any other party any communication with respect to this Agreement, each such notice, demand, request, consent, approval, declaration or other communication shall be in writing and shall be given in the manner, and deemed received, as provided for in the Security Agreement.

Section 8. TERMINATION OF THIS AGREEMENT. Subject to Section 6 hereof, this Agreement shall terminate upon the payment in full in cash of all Obligations (except for contingent indemnity claims for which no claim has been made).


Section 9. GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND PERFORMED IN SUCH STATE, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAW.

[Signature Pages Follow]


IN WITNESS WHEREOF, each Grantor has executed this Intellectual Property Security Agreement as of the date first written above.

GRANTORS:

9 METERS BIOPHARMA, INC.

By: 
Name: Bethany Sensenig
Title: Chief Financial Officer


NAIA RARE DISEASES, LLC

By: 
Name: John Temperato
Title: President

[Signature Page to Intellectual Property Security Agreement]

ACCEPTED AND ACKNOWLEDGED BY
SECURED PARTY:

HIGH TRAIL SPECIAL SITUATIONS LLC
as the Secured Party

By: 
Name: Eric Helenek
Title: Authorized Signatory

[Signature Page to Intellectual Property Security Agreement]


TRADEMARK
REEL: 008037 FRAME: 0808

SCHEDULE I

Trademarks

MARK	DETAILS	GOODS/SERVICES	OWNER
9METERS BIOPHARMA Disclaims: "BIOPHARMA" Jurisdiction: US Reg: 6725571 Serial: 88983913	Registered 05/24/2022 Pub: 12/24/2019 Filed: 08/09/2019	042 pharmaceutical research and development services; medical and scientific research information in the field of novel pharmaceutical discovery and development; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others of new therapeutic entities (ntes) defined as pharmacological treatments based on molecules that are already approved for other indications that are neither new chemical entities (nces) nor generics and new chemical entities (nces) and biologic license application (blas) as novel pharmaceutical treatments; research and development in the field of new therapeutic entities (ntes) defined as pharmacological treatments based on molecules that are already approved for other indications that are neither new chemical entities (nces) nor generics and new chemical entities (nces) and biologic license application (blas) as novel pharmaceutical treatments; research and development in the field of novel pharmaceutical treatments and clinical trials; providing medical and scientific research information in the field of novel pharmaceutical treatments and clinical trials; clinical trials services for others	9 Meters Biopharma, Inc. 8480 Honeycutt Road, Suite 120 Raleigh NORTH CAROLINA 27615
9METERS BIOPHARMA Disclaims: "BIOPHARMA" Jurisdiction: US Serial: 88573419	Published Pub: 12/24/2019 Filed: 08/09/2019	005 pharmaceutical and biological preparations for the treatment of anorectal diseases and gastrointestinal and liver disorders; targeted pharmacological and biological treatments for anorectal diseases, liver, and gastrointestinal disorders such as fecal incontinence, pruritus ani, and radiation proctitis; prescription and non-prescription pharmacological and biological treatments administered in various pharmaceutical technological forms namely, in solid form pills, tablets, capsules, caplets, sachets, in semi-liquid form namely, gels, ointments and pastes, suppositories, in liquid form namely, drops, injectables, infusions, in gaseous form namely, inhalants, or in sprays, namely, intranasally administered medications, for the treatment of anorectal diseases and gastrointestinal illnesses and disorders; capsules sold empty for pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; suppositories with proprietary delivery system for the precise delivery of drugs that target conditions and diseases of the anorectal region; suppositories	9 Meters Biopharma, Inc. 8480 Honeycutt Road, Suite 120 Raleigh NORTH CAROLINA 27615

MARK	DETAILS	GOODS/SERVICES	OWNER
<p>NINEMETERS BIOPHARMA</p> <p>Disclaims: "BIOPHARMA"</p> <p>Jurisdiction: US</p> <p>Serial: <u>88573422</u></p>	<p>Published Pub: 12/24/2019 Filed: 08/09/2019</p>	<p>005 pharmaceutical and biological preparations for the treatment of anorectal diseases and gastrointestinal and liver disorders; targeted pharmacological and biological treatments for anorectal diseases, liver, and gastrointestinal disorders such as fecal incontinence, pruritus ani, and radiation proctitis; prescription and non-prescription pharmacological and biological treatments administered in various pharmaceutical technological forms namely, in solid form pills, tablets, capsules, caplets, sachets, in semi-liquid form namely, gels, ointments and pastes, suppositories, in liquid form namely, drops, injectables, infusions, in gaseous form namely, inhalants, or in sprays, namely, intranasally administered medications, for the treatment of anorectal diseases and gastrointestinal illnesses and disorders; capsules sold empty for pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; suppositories with proprietary delivery system for the precise delivery of drugs that target conditions and diseases of the anorectal region; suppositories</p> <p>042 pharmaceutical research and development services; medical and scientific research information in the field of novel pharmaceutical discovery and development; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others of new therapeutic entities (ntes) defined as pharmacological treatments based on molecules that are already approved for other indications that are neither new chemical entities (nces) nor generics and new chemical entities (nces) and biologic license application (blas) as novel pharmaceutical treatments; research and development in the field of new therapeutic entities (ntes) defined as pharmacological treatments based on molecules that are already approved for other indications that are neither new chemical entities (nces) nor generics and new chemical entities (nces) and biologic license application (blas) as novel pharmaceutical treatments; research and development in the field of novel pharmaceutical treatments and clinical trials; providing medical and scientific research information in the field of novel pharmaceutical treatments and clinical trials; clinical trials services for others</p>	<p>9 Meters Biopharma, Inc. 8480 Honeycutt Road, Suite 120 Raleigh NORTH CAROLINA 27615</p>

MARK	DETAILS	GOODS/SERVICES	OWNER
<p>IT'S NOT YOUR FAULT GLUTEN IS EVERYWHERE</p> <p>Jurisdiction: US</p> <p>Serial: 97363084</p>	<p>Pending New Application Filed: 04/14/2022</p>	<p>035 medical personnel and subject recruitment services for clinical trial studies; conducting pre and post market study surveillance in the field of medical and scientific clinical trials medical personnel and subject recruitment services for clinical trial studies relating to celiac disease and gastrointestinal conditions; conducting pre and post market study surveillance in the field of medical and scientific clinical trials relating to celiac disease and gastrointestinal conditions</p> <p>042 medical and scientific research related to celiac disease and gastrointestinal conditions; pharmaceutical research and development services; testing of pharmaceutical treatments; medical and scientific research information in the field of novel pharmaceutical discovery and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, providing analysis of data obtained from clinical trial studies</p>	<p>9 Meters Biopharma, Inc. 8480 Honeycutt Road, Suite 120 Raleigh NORTH CAROLINA 27615</p>
<p>9METERS BIOPHARMA</p> <p>Disclaims: "BIOPHARMA"</p> <p>Jurisdiction: US</p> <p>Serial: 90600366</p> 	<p>Published Pub: 12/14/2021 Filed: 03/24/2021 Current Basis: ITU Notice Of Allowance Issued -</p>	<p>005 pharmaceutical and biological preparations for the treatment of anorectal diseases and gastrointestinal and liver disorders; targeted pharmacological and biological treatments for anorectal diseases, liver, and gastrointestinal disorders such as fecal incontinence, pruritus ani, and radiation proctitis; prescription and non-prescription pharmacological and biological treatments administered in various pharmaceutical technological forms, namely, in solid form pills, tablets, capsules, caplets, sachets, in semi-liquid form, namely, gels, ointments and pastes, suppositories, in liquid form, namely, drops, injectables, infusions, in gaseous form, namely, inhalants, or in sprays, namely, intranasally administered medications, for the treatment of anorectal diseases and gastrointestinal illnesses and disorders; capsules sold empty for pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; suppositories with proprietary delivery system for the precise delivery of drugs that target conditions and diseases of the anorectal region; suppositories</p> <p>042 pharmaceutical research and development services; medical and scientific research information in the field of novel pharmaceutical discovery and development; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others of new therapeutic entities (ntes) defined as pharmacological treatments based on molecules that are already approved for other</p>	<p>9 Meters Biopharma, Inc. 8480 Honeycutt Road, Suite 120 Raleigh NORTH CAROLINA 27615</p>

MARK	DETAILS	GOODS/SERVICES	OWNER
		<p>indications that are neither new chemical entities (nces) nor generics and new chemical entities (nces) and biologic license application (blas) as novel pharmaceutical treatments; research and development in the field of new therapeutic entities (ntes) defined as pharmacological treatments based on molecules that are already approved for other indications that are neither new chemical entities (nces) nor generics and new chemical entities (nces) and biologic license application (blas) as novel pharmaceutical treatments; research and development in the field of novel pharmaceutical treatments and clinical trials; providing medical and scientific research information in the field of novel pharmaceutical treatments and clinical trials; clinical trials services for others</p>	
<p>IT'S NOT YOUR FAULT</p> <p>Jurisdiction: US</p> <p>Serial: 97363082</p>	<p>Pending New Application Filed: 04/14/2022</p>	<p>035 medical personnel and subject recruitment services for clinical trial studies; conducting pre and post market study surveillance in the field of medical and scientific clinical trials medical personnel and subject recruitment services for clinical trial studies relating to celiac disease and gastrointestinal conditions; conducting pre and post market study surveillance in the field of medical and scientific clinical trials relating to celiac disease and gastrointestinal conditions</p> <p>042 medical and scientific research related to celiac disease and gastrointestinal conditions; pharmaceutical research and development services; testing of pharmaceutical treatments; medical and scientific research information in the field of novel pharmaceutical discovery and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, providing analysis of data obtained from clinical trial studies</p>	<p>9 Meters Biopharma, Inc. 8480 Honeycutt Road, Suite 120 Raleigh NORTH CAROLINA 27615</p>
<p>CEDLARA</p> <p>Jurisdiction: US</p> <p>Reg: 6647940</p> <p>Serial: 90263172</p>	<p>Registered 02/15/2022 Pub: 04/27/2021 Filed: 10/19/2020</p>	<p>042 pharmaceutical research and development services; medical and scientific research information in the field of novel pharmaceutical discovery and development; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others of new therapeutic entities (ntes) defined as pharmacological treatments based on molecules that are already approved for other indications that are neither new chemical entities (nces) nor generics and new chemical entities (nces) and biologic license application (blas) as novel pharmaceutical treatments; research and development in the field of new therapeutic entities (ntes) defined as pharmacological</p>	<p>9 Meters Biopharma, Inc. 8480 Honeycutt Road, Suite 120 Raleigh NORTH CAROLINA 27615</p>

MARK	DETAILS	GOODS/SERVICES	OWNER
		<p>treatments based on molecules that are already approved for other indications that are neither new chemical entities (nces) nor generics and new chemical entities (nces) and biologic license application (blas) as novel pharmaceutical treatments; research and development in the field of novel pharmaceutical treatments and clinical trials; providing medical and scientific research information in the field of novel pharmaceutical treatments and clinical trials; clinical trials services for others; all of the foregoing related to celiac disease</p>	

SCHEDULE II

Patents

ML Ref.	Title	Application No.	Appl. Date	Regis. No.	Status (Exp. Date)	Country
NMT-001-01*	COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING ENVIRONMENTAL ENTEROPATHY	16/484,486	Feb-12-2018		Pending (Feb. 12, 2038 expected)	United States of America
NMT-001-02**	COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH PERMEABILITY OF INTESTINAL EPITHELIUM	16/484,497	Feb-12-2018	11,058,902	Granted (Feb. 12, 2038)	United States of America
NMT-001-02C2**	COMPOSITIONS AND METHODS FOR TREATING DISEASE ASSOCIATED WITH PERMEABILITY OF INTESTINAL EPITHELIUM	17/344,172	Jun-10-2021		Pending (Feb. 12, 2038 expected)	United States of America
NMT-011C1***	COMPOSITIONS AND METHODS FOR TREATING SJOGREN'S DISEASE	17/517,886	May-06-2020		Pending (May 6, 2040 expected)	United States of America
NMT-016	COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INTESTINAL PARACELLULAR PERMEABILITY	16/971,741	Feb-25-2019		Pending (Feb. 25, 2039 expected)	United States of America
NMT-017	COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE CHECKPOINT INHIBITOR THERAPY	16/982,115	Mar-19-2019		Pending (Mar. 19, 2039 expected)	United States of America
NMT-017CP	COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE CHECKPOINT INHIBITOR THERAPY	17/172,387	Feb-10-2021		Pending (Mar. 19, 2039 expected)	United States of America

ML Ref.	Title	Application No.	Appl. Date	Regis. No.	Status (Exp. Date)	Country
NMT-017CPC1	COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE CHECKPOINT INHIBITOR THERAPY	17/239,056	Apr-23-2021	11,278,587	Registered Mar. 19, 2039)	United States of America
NMT-018	COMPOUNDS AND METHODS FOR TREATING TIGHT JUNCTION PERMEABILITY	16/971,739	Feb-25-2019		Pending (Feb. 25, 2039 expected)	United States of America
NMT-019	COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HYPERGLYCEMIA, INSULIN RESISTANCE, AND ASSOCIATED ORGAN DAMAGE	17/046,013	Apr-08-2019		Pending (Apr. 8, 2039 expected)	United States of America
NMT-023	LARAZOTIDE FORMULATIONS	17/635,441	Aug-14-2020		Pending (Aug. 14, 2040 expected)	United States of America
NMT-038PR****	COMPOSITIONS AND METHODS FOR INHIBITING RHO KINASE	63/308,330	Feb-09-2022		Pending (potential term to Feb. 9, 2043)	Provisional

* Co-owned with University of Maryland, Baltimore

** Co-owned with North Carolina State University

*** Co-owned with Oklahoma Medical Research Foundation

**** Co-owned with University of Maryland, College Park

ML Ref.	Title	Application No.	Appl. Date	Regis. No.	Status (Exp. date)	Country
NMT-022	COMPOSITION AND METHODS FOR RECTAL DELIVERY OF 4-AAPA AND 5-ASA COMPOUNDS	17/602,848	Apr-13-2020		Pending (Apr. 13, 2040 expected)	United States of America
NMT-031	COMPOSITIONS AND METHODS FOR TREATING ULCERATIVE COLITIS	17/392,483	Aug-3-2021		Pending (Aug. 3, 2041 expected)	United States of America

Docket ref.	Title	Application No.	Appl. Date	Regis. No.	Status (Exp. Date)	Country
NMT-039PR	COMPOSITIONS AND METHODS FOR TREATING POSTURAL TACHYCARDIA SYNDROME	63/349,630	Jun. 7, 2022		Pending (provides term to Jun 7, 2043)	Provisional

SCHEDULE III

Copyrights

None